Intuitive Surgical Stock Price and Value Analysis

Intuitive Surgical (NasdaqGS:ISRG) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Intuitive Surgical to reach your target.

Target type

ISRG Free Cash Flow Trend

Free Cash Flow trendline for ISRG
Free Cash Flow trendline for Intuitive Surgical
CSV

Based on historical returns, we believe that Intuitive Surgical can grow its free cash at a rate of about 12%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company has stable growth.
  • This company is making money at a great rate!
  • This company is very stable.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the ISRG Numbers

ISRG Price
(Intuitive Surgical stock price per share)
$399.05
[?] ISRG Fair Price
(based on intrinsic value)
$115.88
[?] ISRG Safety Price (based on a variable margin of safety) $92.70
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 138% higher than other Healthcare stocks
[?] PE Ratio versus Industry 100% higher than other Medical Instruments & Supplies stocks
[?] Cash Yield 0.58%
[?] Free Cash Flow Jitter 21%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 7,058,186 shares shorted. With 344,622,785 shares available for purchase and an average trading volume over the past 10 trading days of 1,977,500, it would take at least 3.6 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 1035267 182
2008 1035267 213
2009 1035267 331
2010 1035267 476
2011 1035267 605
2012 1035267 724
2013 1035267 790
2014 1035267 564
2015 1035267 709
2016 1035267 995
2017 1035267 1,037
2018 1035267 1,046
2019 1035267 1,410
2020 1035267 1,245
2021 1035267 1,792
2022 1035267 1,126
2023 1035267 1,273
2024 1035267 1,737
2025 1035267 2,313

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 19 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $22,588 million against net income of $18,774 million, or 1.20 times.

In 2025, operating cash flow was 1.06 times net income, compared with 1.51 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $540 million, 17.8% of operating cash flow of $3,031 million, which leaves an estimated $2,491 million after capex. Across the 19 years with reported capex, it averaged 24.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 1.06, at least 0.25 under the 1.51 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 145 206 24 1.42
2008 204 278 106 1.36
2009 233 392 53.4 1.69
2010 382 546 96 1.43
2011 495 678 82.9 1.37
2012 657 814 114 1.24
2013 671 880 105 1.31
2014 419 665 106 1.59
2015 589 806 81 1.37
2016 738 1,087 53.9 1.47
2017 671 1,144 191 1.71
2018 1,128 1,170 187 1.04
2019 1,379 1,598 426 1.16
2020 1,061 1,485 342 1.40
2021 1,705 2,089 340 1.23
2022 1,322 1,491 532 1.13
2023 1,798 1,814 1,064 1.01
2024 2,323 2,415 1,111 1.04
2025 2,856 3,031 540 1.06

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2013 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $11,462 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 9 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $10,290 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $2,295 million, 99.2% of estimated free cash flow of $2,313 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2013 790 n/a 1,109 1,109 140.4%
2014 564 n/a 1,000 1,000 177.2%
2015 709 n/a 184 184 25.9%
2016 995 n/a 42.5 42.5 4.3%
2017 1,037 n/a 2,274 2,274 219.3%
2019 1,410 n/a 270 270 19.1%
2020 1,245 n/a 134 134 10.8%
2022 1,126 n/a 2,607 2,607 231.7%
2023 1,273 n/a 416 416 32.7%
2025 2,313 n/a 2,295 2,295 99.2%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $601 million in 2007 and $10,065 million in 2025, a compound annual growth rate of 17.0% over 18 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 20.5% from 2024 to 2025.

Our estimated free cash flow was $2,313 million in 2025, 23.0% of revenue. In 2007 the estimated margin was 30.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 601 182 30.2%
2008 875 213 24.4%
2009 1,052 331 31.5%
2010 1,413 476 33.7%
2011 1,757 605 34.4%
2012 2,179 724 33.2%
2013 2,265 790 34.9%
2014 2,132 564 26.5%
2015 2,384 709 29.7%
2016 2,704 995 36.8%
2017 3,129 1,037 33.1%
2018 3,724 1,046 28.1%
2019 4,479 1,410 31.5%
2020 4,358 1,245 28.6%
2021 5,710 1,792 31.4%
2022 6,222 1,126 18.1%
2023 7,124 1,273 17.9%
2024 8,352 1,737 20.8%
2025 10,065 2,313 23.0%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $3,368 million against total liabilities of $2,517 million, or 133.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 12.3% of total assets in 2025, compared with 14.1% in 2008, a decrease of 1.8 percentage points.

Stockholders equity was $17,942 million in 2025, compared with $1,267 million in 2008, a rise of 1316.4%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 15.3% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 1,475 195 208 1,267
2009 1,810 221 272 1,537
2010 2,390 280 353 2,037
2011 3,063 466 418 2,646
2012 4,059 554 479 3,580
2013 3,950 782 449 3,501
2014 3,959 600 580 3,379
2015 4,907 715 588 4,320
2016 6,487 1,037 666 5,778
2017 5,777 648 996 4,780
2018 7,847 858 1,159 6,688
2019 9,733 1,168 1,449 8,285
2020 11,169 1,623 1,410 9,759
2021 13,555 1,291 1,604 11,952
2022 12,974 1,581 1,861 11,113
2023 15,442 2,750 2,044 13,397
2024 18,743 2,027 2,214 16,530
2025 20,459 3,368 2,517 17,942

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $399.05, our model's value equals that price if free cash flow grows an average of 35.8 percent a year over the 10 projection years. Our model assumes 12.2 percent a year for this stock, so the price implies growth of 35.8 percent, which is above the 12.2 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 35.8 percent a year, free cash flow would grow about 21.3 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $807 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $319.24 32.0%
Current price $399.05 35.8%
20 percent above the current price $478.86 38.9%
Our model (stored fair price) $115.88 12.2%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Free cash flow was positive in all 19 fiscal years we have for Intuitive Surgical under its current SEC filer.

Intuitive Surgical's average free cash flow rose sharply, from $242 million in its earliest three years to $1,774 million in its latest three.

Free cash flow is fairly steady from year to year, with a variability measure of 21%.

Intuitive Surgical is priced at $399.05, above our fair value estimate of $115.88 and its safe value of $92.70.

Dividends are not in our data for Intuitive Surgical.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 138% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% above the average for stocks in the Medical Instruments & Supplies industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Instruments & Supplies industry, the ones closest in market capitalization to Intuitive Surgical, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Intuitive Surgical (ISRG) 138,328 48.3 - 0.6% 244% above
Edwards Lifesciences Corporation (EW) 58,564 59.2 - 0.9% 148% above
Zimmer Biomet Holdings (ZBH) 19,134 25.5 0.9% - 51% above
The Cooper Companies (COO) 11,196 20.2 - 3.0% 17% below
MSA Safety Incorporated (MSA) 6,550 21.8 1.2% 0.8% 277% above
DENTSPLY SIRONA (XRAY) 1,653 - 1.9% 33.8% 84% below
Alpha Pro Tech, Ltd. (APT) 61.2 12.2 - - 2% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1035267.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ISRG annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ISRG

Does Intuitive Surgical have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ISRG

This example shows how we apply the Trendshare checklist to ISRG: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 399.05
    • Market cap: $138B
    • EPS: 8.27
  2. Step 2 — Valuation checks

    • P/E: 48.253
    • FCF yield: 0.6%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.